Alembic Pharmaceuticals Receives USFDA Nod for Psoriasis Treatment

Alembic Pharmaceuticals has obtained approval from the US Food & Drug Administration to market Betamethasone Valerate Foam, a generic medication for treating moderate-to-severe psoriasis of the scalp. This product is therapeutically equivalent to Luxiq Foam by Norvium Bioscience. Alembic's stock saw a slight dip following the announcement.

Alembic Pharmaceuticals announced on Monday that it has received approval from the US health regulator to market a generic medication specifically for treating moderate-to-severe psoriasis of the scalp.

The company stated that the US Food & Drug Administration (USFDA) granted final approval for its abbreviated new drug application (ANDA) for Betamethasone Valerate Foam. This product is deemed therapeutically equivalent to the reference drug Luxiq Foam (0.12%), produced by Norvium Bioscience, LLC.

Betamethasone Valerate Foam serves as a topical corticosteroid that provides relief for inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses of the scalp. Shares of Alembic Pharmaceuticals fell by 0.97%, closing at Rs 1,089.90 per piece on the BSE on Monday.

(With inputs from agencies.)